← Back to Search

Other

Neurovascular Responses to Hot Flashes

N/A

Recruiting

Led By Sarah Baker, PhD

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Not taking medications influencing cardiovascular function

Free from cardiovascular disease

Timeline

Screening 3 weeks

Treatment Varies

Follow Up continuous measurement of vascular conductance during infusion of each drug- 3min at baseline and at each drug dose (~60min total of continuous forearm vascular conductance measurements)

Awards & highlights

No Placebo-Only Group

Summary

This trial looks at how hot flashes affect women's risk for cardiovascular disease.

Who is the study for?

This trial is for non-obese women who are not on cardiovascular medications, have at least one ovary, do not smoke, and are free from cardiovascular diseases. It aims to understand the connection between hot flashes during menopause and risks of hypertension.

What is being tested?

The study tests how substances like Norepinephrine affect blood vessels and heart function in women with hot flashes. It looks at body responses to stressors and drugs that influence blood pressure and flow during menopausal changes.

What are the potential side effects?

Possible side effects may include changes in blood pressure or heart rate due to Norepinephrine or other agents used. Participants might also experience discomfort from sympathoexcitatory stressors applied during the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am not on any medications that affect heart function.

Select...

I do not have any heart diseases.

Select...

I have at least one ovary.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ continuous measurement of vascular conductance during infusion of each drug- 3min at baseline and at each drug dose (~60min total of continuous forearm vascular conductance measurements)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~continuous measurement of vascular conductance during infusion of each drug- 3min at baseline and at each drug dose (~60min total of continuous forearm vascular conductance measurements)

This trial's timeline: 3 weeks for screening, Varies for treatment, and continuous measurement of vascular conductance during infusion of each drug- 3min at baseline and at each drug dose (~60min total of continuous forearm vascular conductance measurements) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Compare microvascular function in women with low and high frequency hot flashes

Compare sympathetic function in women with low and high frequency hot flashes

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Experimental: Healthy Women VolunteersExperimental Treatment5 Interventions

Hot Flash frequency will be assessed in the study subjects during a screening period. Participants can then chose to participate 1 or 2 study visits- Protocol 1: Microvascular function and/or Protocol 2: Autonomic function

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Sodium Nitroprusside

2018

Completed Phase 1

~240

Norepinephrine

2014

Completed Phase 4

~1780